Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study

Jill E. Lavigne, William T. Shearer, Bruce Thompson, E. John Orav, Thomas J. Starc, Steven D. Colan, Ricardo Pignatelli, Sharon E. O'Brien, Louis Bezold, Phillip LaRusa, Kirk A. Easley, Irene Cheng, Sarah A. Duffy, Steven E. Lipshultz

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Seroreverters (uninfected children of HIV-infected mothers) have exhibited left ventricular (LV) dysfunction. Mitochondrial toxicity associated with in utero of postnatal exposure to highly active antiretroviral therapy (HAART) is a possible mechanism. Adult and animal models have demonstrated associations between LV abnormalities, cardiomyopathy, and components of HAART. Yet, outcomes in children are poorly understood. In this study, we explore HAART-associated LV abnormalities in seroreverters exposed to HAART (n = 144) or never exposed (n = 252). Subjects are drawn from the Women and Infants Transmission Study and the Pediatric Pulmonary and Cardiovascular Complications of HIV Study, respectively. Data include (1) echocardiographic studies of LV structure and function and (2) serologic cardiac biomarkers (cardiac troponin, probrain natriuretic peptide, high-sensitivity C reactive protein), both collected during the first month of life, and again at 6, 12, 24, 36, and 48 months postnatally. Planned analyses include several regression models. At this time, we have access to data for all 252 unexposed children, and 53 exposed subjects are enrolled. The cohorts are similar in terms of gender and race and the recruited subjects are representative of all eligible subjects in terms of exposure to HAART. Recruitment will continue into 2006.

Original languageEnglish (US)
Pages (from-to)187-197
Number of pages11
JournalCardiovascular Toxicology
Volume4
Issue number2
DOIs
StatePublished - Oct 14 2004

Keywords

  • Antiretroviral therapy
  • Cardiovascular
  • Highly active antiretroviral therapy
  • HIV
  • Mitochondria
  • Prophylaxis
  • Seroreverter
  • Study design
  • Toxicity
  • Vertical transmission

ASJC Scopus subject areas

  • Toxicology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study'. Together they form a unique fingerprint.

  • Cite this

    Lavigne, J. E., Shearer, W. T., Thompson, B., Orav, E. J., Starc, T. J., Colan, S. D., Pignatelli, R., O'Brien, S. E., Bezold, L., LaRusa, P., Easley, K. A., Cheng, I., Duffy, S. A., & Lipshultz, S. E. (2004). Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study. Cardiovascular Toxicology, 4(2), 187-197. https://doi.org/10.1385/CT:4:2:187